Palisade Bio Inc
7NS0
Company Profile
Business description
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
Contact
4600 South Syracuse Street
Suite 900
DenverCO80237
USAT: +1 858 704-4900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
14
Stocks News & Analysis
stocks
This ASX miner is the cheapest in our iron ore coverage
High debt levels and low commodity prices were a concern, but agreed sell-downs and a ramp-up of key operations should help.
stocks
Apple names new CEO as Tim Cook steps aside after 15 years
John Ternus, Apple’s hardware chief, will take up the role in September.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,084.70 | 40.50 | -0.44% |
| CAC 40 | 8,235.72 | 95.32 | -1.14% |
| DAX 40 | 24,270.87 | 146.93 | -0.60% |
| Dow JONES (US) | 49,149.38 | 293.18 | -0.59% |
| FTSE 100 | 10,498.09 | 110.99 | -1.05% |
| HKSE | 26,133.61 | 353.87 | -1.34% |
| NASDAQ | 24,259.96 | 144.43 | -0.59% |
| Nikkei 225 | 59,531.56 | 182.39 | 0.31% |
| NZX 50 Index | 12,945.60 | 13.27 | 0.10% |
| S&P 500 | 7,064.01 | 45.13 | -0.63% |
| S&P/ASX 200 | 8,856.20 | 40.60 | -0.46% |
| SSE Composite Index | 4,101.00 | 15.92 | 0.39% |